TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS WITH NEGATIVE PROGRAMMED CELL DEATH LIGAND EXPRESSION

Abstract

Summary. Lung cancer remains one of the most commonly diagnosed and fatal oncological diseases in the world. Patients with metastatic non-small cell lung cancer and programmed cell death ligand-1 expression less than 1% constitute a significant and difficult-to-treat population. According to meta-analyses, the combination of immunotherapy and platinum-based chemotherapy significantly improves progression-free survival, overall survival, and objective response rate in these patients compared with chemotherapy alone.